Press releases

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

Boston Scientific will participate in the upcoming healthcare conference in May 2019. A live webcast and replay will be available.

New stent system now available for treating patients with deep venous blockages.

Results includes data about Boston Scientific S-ICD, POLARx cryoablation catheter, WATCHMAN device and LUX-Dx insertable cardiac monitor.

Boston Scientific will participate in the upcoming investor healthcare conference in May 2019. A live webcast and replay will be available.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.

Transcatheter aortic valve replacement technology for patients with severe aortic stenosis designed to minimize paravalvular leakage, offer controlled delivery and repositionability post deployment.

The inaccessibility of these products will severely limit treatment options for the 50% of women in the U.S. who will suffer from POP during their lives.

Boston Scientific will webcast its conference call with financial results and business highlights for Q1 ended March 31, 2019.

New data showcases safety & efficacy of recently acquired RF balloon-based, single-shot ablation technology when treating patients with AFib.

Company begins limited market release in Europe for next generation WATCHMAN device, intended to reduce the risk of stroke in people with non-valvular AFib.

Key data to be featured at European Heart Rhythm Association (EHRA) Congress include outcomes from the LUMINIZE RF balloon catheter for the treatment of AFib.

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions.

Boston Scientific will participate in the upcoming healthcare conference in February 2019. A live webcast and replay will be available.

Boston Scientific Corporation (NYSE: BSX) announced its completed public offering of senior notes.

Boston Scientific Corporation (NYSE: BSX) announced the pricing of a public offering of senior notes.

Boston Scientific will participate in the SVB Leerink healthcare conference in February 2019. A live webcast and replay will be available.

Patient safety is always our highest priority at Boston Scientific.

"Meaningful innovation and focused execution helped us deliver strong financial results in 2018," said CEO Mike Mahoney.

Rezūm patients experienced significant and sustained improvement in benign prostatic hyperplasia (BPH) symptoms and quality of life.

Advanced systems offer customizable therapy to treat Parkinson's symptoms.

Boston Scientific venous stent met VIRTUS trial primary effectiveness and safety endpoints in re-establishing blood flow.

All patent litigation between the companies to be dismissed.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 2018 and the full 2018 year.